4,047 Shares in Elevance Health, Inc. $ELV Bought by Integrated Quantitative Investments LLC

Integrated Quantitative Investments LLC purchased a new stake in Elevance Health, Inc. (NYSE:ELV) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,047 shares of the company’s stock, valued at approximately $1,574,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Larson Financial Group LLC grew its position in Elevance Health by 34.9% during the first quarter. Larson Financial Group LLC now owns 584 shares of the company’s stock worth $254,000 after buying an additional 151 shares in the last quarter. Bailard Inc. lifted its position in shares of Elevance Health by 6.9% in the 1st quarter. Bailard Inc. now owns 1,793 shares of the company’s stock worth $780,000 after acquiring an additional 116 shares during the period. Private Advisor Group LLC grew its holdings in shares of Elevance Health by 4.9% during the 1st quarter. Private Advisor Group LLC now owns 9,970 shares of the company’s stock worth $4,337,000 after purchasing an additional 468 shares in the last quarter. Formidable Asset Management LLC bought a new stake in shares of Elevance Health during the first quarter valued at approximately $222,000. Finally, Csenge Advisory Group raised its stake in shares of Elevance Health by 2.6% in the first quarter. Csenge Advisory Group now owns 3,497 shares of the company’s stock valued at $1,484,000 after purchasing an additional 87 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ELV shares. Argus reiterated a “hold” rating on shares of Elevance Health in a research note on Monday, July 21st. Bank of America lifted their target price on shares of Elevance Health from $330.00 to $370.00 and gave the company a “neutral” rating in a research report on Friday, October 10th. Truist Financial set a $400.00 target price on shares of Elevance Health in a research note on Tuesday, October 14th. Robert W. Baird cut their price target on shares of Elevance Health from $492.00 to $297.00 and set a “neutral” rating for the company in a research note on Friday, July 25th. Finally, Guggenheim lifted their price objective on Elevance Health from $360.00 to $398.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Twelve equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Elevance Health currently has an average rating of “Hold” and a consensus target price of $397.33.

Elevance Health Price Performance

NYSE:ELV opened at $325.94 on Friday. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. The firm has a market cap of $72.44 billion, a PE ratio of 13.33, a price-to-earnings-growth ratio of 1.23 and a beta of 0.60. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75. The company’s 50-day moving average price is $329.73 and its two-hundred day moving average price is $341.33.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Tuesday, October 21st. The company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.03 by $1.00. The company had revenue of $50.09 billion during the quarter, compared to analyst estimates of $49.26 billion. Elevance Health had a net margin of 2.84% and a return on equity of 16.17%. The company’s revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the business posted $8.37 earnings per share. On average, equities analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 19th. Shareholders of record on Friday, December 5th will be paid a $1.71 dividend. The ex-dividend date of this dividend is Friday, December 5th. This represents a $6.84 dividend on an annualized basis and a yield of 2.1%. Elevance Health’s payout ratio is currently 27.96%.

Insider Buying and Selling

In other Elevance Health news, Director Susan D. Devore bought 1,200 shares of the stock in a transaction dated Tuesday, August 19th. The stock was bought at an average cost of $312.15 per share, for a total transaction of $374,580.00. Following the completion of the purchase, the director owned 3,502 shares in the company, valued at $1,093,149.30. This represents a 52.13% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.29% of the company’s stock.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.